Two dose levels of ifosfamide in malignant mesothelioma
LUNG CANCER, vol.15, no.2, pp.207-213, 1996 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 15 Issue: 2
- Publication Date: 1996
- Doi Number: 10.1016/0169-5002(96)00584-3
- Journal Name: LUNG CANCER
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.207-213
- Keywords: malignant mesothelioma, dose-response, ifosfamide, PLEURAL MESOTHELIOMA, ONCOLOGY-GROUP, MESNA
- Ankara University Affiliated: Yes
Abstract
Thirty-one consecutive patients with histologically proven and symptomatic malignant mesothelioma were treated with two dose levels of ifosfamide. The first group of 15 patients were given 2.3 g/m(2)/day for 5 days (group A) and the following 16 patients were treated with 1.2 g/m(2)/day for 5 days of ifosfamide (group B). Treatment cycles were repeated every 3 weeks. While the partial response rate (PR) in group A was 38.5%, it was only 6.25% in group B (P > 0.05). The 95% confidence interval for the difference in PR rates was 3.3-61.2%. The overall survival (OAS) of groups A and B were similar (8 months and 9 months, respectively). Higher Grade 3-4 myelotoxicity was observed in group A when compared to group B (30.8% vs. 18.7%; P > 0.05). In conclusion, a favourable response rate could be achieved in malignant mesothelioma with high dose ifosfamide at the cost of increased toxicity.